Reifsnider OS, Kansal AR, Wanner C, Pfarr E, et al. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG Outcome Trial. Am J Kidney Dis 2021 Nov 6. pii: S0272-6386(21)00952.
PMID: 34752913